Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Clearside Biomedical, Inc. (CLSD : NSDQ)
 
 • Company Description   
Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.45 Daily Weekly Monthly
20 Day Moving Average: 287,305 shares
Shares Outstanding: 60.15 (millions)
Market Capitalization: $87.22 (millions)
Beta: 2.15
52 Week High: $7.73
52 Week Low: $1.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.65% -1.61%
12 Week -0.68% 9.19%
Year To Date -47.27% -35.58%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
900 NORTH POINT PARKWAY SUITE 200
-
ALPHARETTA,GA 30005
USA
ph: 678-270-3631
fax: 678-270-4033
ir@clearsidebio.com http://www.clearsidebio.com
 
 • General Corporate Information   
Officers
George Lasezkay - President; Chief Executive Officer and Director
Charles A. Deignan - Chief Financial Officer
Christy L. Shaffer - Director
Clay B. Thorp - Director
Benjamin R. Yerxa - Director

Peer Information
Clearside Biomedical, Inc. (CORR.)
Clearside Biomedical, Inc. (RSPI)
Clearside Biomedical, Inc. (CGXP)
Clearside Biomedical, Inc. (BGEN)
Clearside Biomedical, Inc. (GTBP)
Clearside Biomedical, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 185063104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 60.15
Most Recent Split Date: (:1)
Beta: 2.15
Market Capitalization: $87.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.75
Price/Cash Flow: 156.17
Price / Sales: 2.92
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -141.94%
Sales Growth
vs. Year Ago Period: 920.59%
vs. Previous Quarter: -98.65%
ROE
03/31/22 - 0.31
12/31/21 - 1.63
09/30/21 - -161.73
ROA
03/31/22 - 0.25
12/31/21 - 1.19
09/30/21 - -98.71
Current Ratio
03/31/22 - 8.49
12/31/21 - 9.08
09/30/21 - 2.90
Quick Ratio
03/31/22 - 8.49
12/31/21 - 9.08
09/30/21 - 2.90
Operating Margin
03/31/22 - 0.28
12/31/21 - 1.27
09/30/21 - -652.60
Net Margin
03/31/22 - 0.28
12/31/21 - 1.27
09/30/21 - -652.60
Pre-Tax Margin
03/31/22 - 0.28
12/31/21 - 1.27
09/30/21 - -652.60
Book Value
03/31/22 - 0.53
12/31/21 - 0.64
09/30/21 - 0.30
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©